Enzastaurin (LY317615) + Carboplatin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Gliomas
Conditions
Recurrent Gliomas
Trial Timeline
Jan 1, 2007 → Jul 1, 2013
NCT ID
NCT01445119About Enzastaurin (LY317615) + Carboplatin
Enzastaurin (LY317615) + Carboplatin is a phase 1 stage product being developed by Eli Lilly for Recurrent Gliomas. The current trial status is completed. This product is registered under clinical trial identifier NCT01445119. Target conditions include Recurrent Gliomas.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01445119 | Phase 1 | Completed |
Competing Products
20 competing products in Recurrent Gliomas